Security Snapshot

Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share (LRMR) Institutional Ownership

CUSIP: 517125100

13F Institutional Holders and Ownership History from Q2 2020 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

162

Shares (Excl. Options)

95,442,400

Price

$3.05

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+7,829,789
Value change
+$14,888,987
Number of holders
162
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
107,502,422
SEC-reported price per share
$4.10
Insider filing price
$4.10
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • LRMR - Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 517125100.
  • 162 institutions reported positions in Q2 2026.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 162 to 162 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $394,797,184 to $291,384,072.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 162 institutions filings for Q2 2026.

Open SEC evidence

Security key

517125100

Latest holder period

Q2 2026

13F holders

162

13D/G owners

6

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
6
Security
LRMR
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Flynn James E 34% -3.9% $123,052,785 +$17,250,000 35,667,474 +16% Deerfield Management Company, L.P. 27 Feb 2026
Blue Owl Capital Holdings LP 10% 0% $54,234,435 +$11,487,886 10,739,492 +27% Blue Owl Capital Holdings LP 31 Mar 2026
Opaleye Management Inc. 4.8% -23% $15,412,500 +$590,966 4,110,000 +4% Opaleye Management, Inc. 29 Aug 2025
MILLENNIUM MANAGEMENT LLC 3.5% -38% $16,313,751 -$6,036,988 3,625,278 -27% Millennium Management LLC 31 Mar 2026
BlackRock, Inc. 4.8% -6% $7,175,619 -$433,939 3,079,665 -5.7% BlackRock, Inc. 31 Mar 2025
GOLDMAN SACHS GROUP INC 4.1% $6,058,491 2,600,211 THE GOLDMAN SACHS GROUP, INC. 31 Mar 2025

As of 30 Jun 2026, 162 institutional investors reported holding 95,442,400 shares of Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share (LRMR). This represents 89% of the company’s total 107,502,422 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
81%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
DEERFIELD MANAGEMENT COMPANY, L.P. 33% 35,606,974 0% 1.1% $108,601,271
Blue Owl Capital Holdings LP 8.5% 9,163,157 +29% 4.2% $27,947,629
BlackRock, Inc. 5.3% 5,678,035 +51% 0% $17,318,006
Defilade Capital Management, L.P. 3.4% 3,670,135 1.5% $11,193,912
Driehaus Capital Management LLC 2.9% 3,163,423 +7.8% 0.06% $9,648,440
VANGUARD CAPITAL MANAGEMENT LLC 2.8% 2,974,901 +3.8% 0% $9,073,448
RTW INVESTMENTS, LP 2.4% 2,565,999 +71% 0.07% $7,826,297
AQR CAPITAL MANAGEMENT LLC 2.2% 2,371,414 +190% 0% $7,232,813
MARSHALL WACE, LLP 1.9% 2,012,458 +116% 0.01% $6,137,996
DAFNA Capital Management LLC 1.9% 2,008,164 -1% 1.2% $6,124,900
GOLDMAN SACHS GROUP INC 1.6% 1,752,910 +12% 0% $5,346,375
GEODE CAPITAL MANAGEMENT, LLC 1.6% 1,679,003 +51% 0% $5,121,921
Qube Research & Technologies Ltd 1.5% 1,641,042 +94% 0.01% $5,005,178
CITADEL ADVISORS LLC 1.4% 1,456,825 +181% 0% $4,443,316
STATE STREET CORP 1.3% 1,411,804 +55% 0% $4,306,002
VANGUARD PORTFOLIO MANAGEMENT LLC 1.3% 1,403,172 +245% 0% $4,279,675
Woodline Partners LP 1.3% 1,400,850 0% 0.01% $4,272,593
MILLENNIUM MANAGEMENT LLC 1.2% 1,333,037 -63% 0% $4,065,763
DIMENSIONAL FUND ADVISORS LP 0.89% 961,083 +20% 0% $2,932,299
FMR LLC 0.87% 937,368 +1375% 0% $2,858,971
SPHERA FUNDS MANAGEMENT LTD. 0.86% 926,004 0.4% $2,824,312
Nuveen, LLC 0.83% 895,304 +33% 0% $2,730,677
Alyeska Investment Group, L.P. 0.57% 617,211 0% 0% $1,882,494
NORTHERN TRUST CORP 0.51% 550,266 +46% 0% $1,678,311
VANGUARD FIDUCIARY TRUST CO 0.42% 448,168 +55% 0% $1,366,912

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
25
Latest
Q2 2026
Rows shown
1-25 of 25
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 95,442,400 $291,384,072 +$14,888,987 $3.05 162
2026 Q1 87,757,044 $394,797,184 +$65,817,605 $4.50 162
2025 Q4 72,707,274 $277,008,552 -$38,772,086 $3.81 137
2025 Q3 85,496,565 $274,794,131 +$75,244,593 $3.23 135
2025 Q2 62,321,311 $180,120,860 +$7,437,034 $2.89 116
2025 Q1 60,827,153 $131,864,050 -$12,271,759 $2.15 101
2024 Q4 63,434,614 $245,492,888 -$5,894,960 $3.87 115
2024 Q3 64,329,070 $421,287,622 -$5,929,383 $6.55 122
2024 Q2 65,308,461 $473,379,696 +$12,179,883 $7.25 105
2024 Q1 63,594,662 $482,627,362 +$182,781,336 $7.59 102
2023 Q4 39,456,509 $179,551,948 +$15,220,703 $4.55 69
2023 Q3 38,745,394 $153,032,401 -$3,458,223 $3.95 63
2023 Q2 39,027,692 $120,194,716 -$3,770,373 $3.13 65
2023 Q1 38,462,442 $174,244,129 +$1,086,191 $4.53 68
2022 Q4 38,766,976 $160,093,910 +$976,279 $4.13 47
2022 Q3 38,715,175 $123,902,000 +$77,822,908 $3.20 52
2022 Q2 14,391,311 $28,222,000 -$2,241,518 $1.96 34
2022 Q1 15,257,103 $61,778,000 -$2,584,495 $4.05 40
2021 Q4 14,567,301 $157,170,000 -$456,088 $10.79 47
2021 Q3 14,519,322 $167,488,004 +$199,976 $11.53 50
2021 Q2 14,543,964 $142,828,000 -$4,477,645 $9.82 42
2021 Q1 14,110,404 $206,147,000 -$8,290,625 $14.61 53
2020 Q4 14,252,270 $305,135,000 +$10,378,818 $21.41 42
2020 Q3 13,625,016 $206,745,000 +$10,359,632 $15.17 37
2020 Q2 12,953,044 $166,142,000 +$166,142,000 $12.85 34
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .